Have you tried to short an OTC stock? The fees are
Have you tried to short an OTC stock? The fees are astronomical compared to the possible gains to be made and that's if you can find a broker who will do it along with the borrows (in 15 years following these I have yet to find either). You would have to risk millions to make a thousand. It makes no sense whatsoever. It does give unscrupulous people an excuse to convince naive others to hold forever though.
the idea of naked shorting on the OTC is ludicrous. A hundred people would have to be involved in a massive conspiracy - all risking their already very lucrative careers plus jailtime - for next to nothing. With RegSHO it would be trivial to identify those people and stop it.
It makes FAR more sense to illegally pump a worthless stock with a bunch of lies than it does to short one. The potential gains are unlimited, unlike shorting.
Nanotech Entertainment Inc. (NTEK) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Introducing the 7406 Incubator Shaker by Caron Scientific Caron Scientific, Inc. has raised the bar in environmental testing and laboratory equipment with the launch of their newest innovation: the 7406 Incubator Shaker. Known for its dedication to providing state-of-the-art incubation solutions, Caron Scientific presented this remarkable product at a prominent...
Continue Reading
US Stocks Look to Rebound Following Recent Sell-Off U.S. stock futures showed an upward trend recently, bouncing back from a notable sell-off. Most benchmark indices are witnessing gains in premarket trading while the small-cap Russell 2000 remains slightly down. Nvidia's Effects on Technology Sector Nvidia Corp. (NASDAQ: NVDA) experienced a significant decline of over 8%...
Continue Reading
Understanding the Avantor, Inc. Class Action Lawsuit Avantor, Inc. (NYSE: AVTR) is a prominent provider of scientific products and services designed to cater to various sectors including biotechnology and pharmaceuticals. This article sheds light on the ongoing class action lawsuit initiated on behalf of investors who acquired shares of Avantor during a specified class...
Continue Reading
Hyphens Pharma Collaborates with Louis Widmer for Cerapro® MED Hyphens Pharma International Limited is thrilled to announce a significant partnership with Louis Widmer SA for the commercialization of their innovative product, Cerapro® MED Skin Barrier Cream. This agreement enables Louis Widmer to promote and distribute Cerapro® MED in six European countries. About...
Continue Reading
Engagement in a Notable Investor Conference Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) has exciting news for its stakeholders! The company recently declared its participation in an essential fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference. This event is set to take place in Boston and will commence at 11:30 a.m. PT / 2:30 p.m. ET on a Tuesday...
Continue Reading
